Join Kazia Therapeutics for a virtual event featuring management’s overview of NDL2, the Company’s novel nuclear PD-L1 protein degrader designed to address mechanisms of immunotherapy resistance in advanced solid tumors, with an initial focus on metastatic breast cancer and colorectal cancer. NDL2 represents a potentially first-in-class approach within the emerging field of protein degradation, a therapeutic category with no known compounds currently in clinical development.

The event will provide an overview of NDL2 and its optimized bicyclic peptide designed to selectively degrade disease-associated nuclear PD-L1 protein and restore the body’s natural anti-tumor immune response. The PD-L1 protein plays an important role in regulating the immune system, but some cancer cells take advantage of this natural mechanism to evade immune detection and resist treatment. Kazia is leading a new frontier with Targeted Protein Degradation (TPD), exploiting naturally occurring protein degradation pathways to disrupt critical cellular processes.

A live question and answer session will follow the formal presentations.

Disclaimer: NDL2 is an investigational, preclinical-stage therapeutic candidate and has not been approved for clinical use. Statements regarding its potential therapeutic benefits and future development are forward-looking and subject to risks and uncertainties. Additional information regarding these risks is available in Kazia Therapeutics’ filings with the U.S. Securities and Exchange Commission.